www.lightstonevc.com Open in urlscan Pro
173.199.178.36  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About
 * Portfolio
 * Team
 * News
 * Contact
 * Login
 * Menu



INVESTING
IN PEOPLE


INVESTING IN MEDICAL BREAKTHROUGHS

Lightstone believes in founders with vision and commitment.



INTRODUCING LIGHTSTONE VENTURES



Learn about how our experienced life science investors are working with
visionary founders to translate novel scientific breakthroughs into clinically
and commercially meaningful therapies.




We are dedicated to empowering visionary entrepreneurs with the resources and
operational guidance necessary to bring their innovative therapeutics to the
patients who need them most.


PROVEN
TEAM

We are experienced life science investors dedicated to translating novel
scientific breakthroughs into clinically and commercially meaningful therapies.
With over 100 years of combined operational experience, there is no hurdle we
haven’t already faced and overcome. We serve as funders and operational partners
as our portfolio companies grow, and we have a proven track record of bringing
approved drugs and devices to patients.


PROVEN
STRATEGY

We invest in early stage, therapeutic-oriented companies across the life science
spectrum, as well as opportunistic late-stage companies. Our over-arching goal
is to find breakthrough therapies that have the potential to change the practice
of medicine. We are thesis-driven and committed to seeking out novel, disruptive
and defensible technologies to meet unmet clinical needs.


PROVEN
RESULTS

We believe that innovation, not incrementalism, drives significant exits and
successful financial returns. Our investment team has led deals resulting in 19
acquisitions and 20 IPOs over the last two decades. We help our portfolio
companies execute their business plans and see their visions become a reality.
Additionally, our strong ties with key players in major life science companies
facilitates strategic partnerships and acquisitions.

Lightstone Ventures was founded in 2012 and leverages over 100 years of combined
operational experience to empower founders with vision and commitment to bring
innovative therapeutics to patients in need.

COMPANY BUILDERS



The Lightstone team collectively has over 75 years of experience in the venture
capital industry, and nearly 100 years of operational experience. The team has
been part of start-up ventures from inception through liquidity and plays a
critical role in helping to source, evaluate, guide and build successful
healthcare companies. We have the resources to provide significant seed-stage
funding but know that fostering successful companies does not just mean writing
a check. We not only back successful companies financially but we partner with
them, bringing a long-term mindset. Our team works hands-on with founders to
help establish a strategy that can transform their vision into commercially
viable products. We are operational partners who do not simply provide guidance
for a board seat but leverage our experience to help founders navigate the
day-to-day functions of their organization.



A CLEAR DIRECTIVE



Using a thesis-driven investment strategy, we focus on understanding key market
sectors and seeking out disruptive technologies while building and nurturing
relationships with key thought leaders. Additionally, our global footprint with
offices in the U.S., Ireland and Singapore allows us to build a network with
non-U.S. strategic and financial funding sources, as well as exploring novel
development and commercialization strategies in these geographies.



STEADY, PROVEN TRACK RECORD



Members of the Lightstone team have been involved in several of the largest
venture-backed life science exits over the last decade including: Ardian,
Acceleron, ALX Oncology, Calithera BioSciences, Claret Medical, Disarm
Therapeutics, MicroVention, Nimbus, Plexxikon, Portola Pharmaceuticals,
Promedior, Proteolix, Ra Pharma, Tizona Therapeutics, Twelve and Zeltiq.

INVESTING TO TRANSFORM PATIENT OUTCOMES


LIGHTSTONE SECTORS


FOCUS:
BIOPHARMACEUTICALS

Our team has a particular interest in companies that are developing
first-in-class drugs, including biologics and neuromodulators for diseases of
the central nervous system (CNS) and pioneering cell and gene therapeutics that
represent a game-changing approach to the delivery of therapy. We are also
interested in next-generation cancer therapeutics that harness the power of the
immune system.


FOCUS:
MEDICAL TECHNOLOGY

We look for founders with big ideas targeting the convergence of technology,
medicine and consumer health. We are interested in companies focused on
personalized medicines and targeted therapeutics that leverage data analytics
and scientific platforms—groundbreaking medical technologies that address major
diseases across immunology, cardiovascular, neurology and ophthalmology.

BRIGHT FUTURES


LIGHTSTONE PORTFOLIO



All Sectors Biopharmaceuticals Medical Technology

--------------------------------------------------------------------------------

All Companies Active Select Exits

--------------------------------------------------------------------------------

All Funds Lightstone Singapore Legacy

X




Select Exits | Biopharmaceuticals

Acceleron Pharma is a clinical-stage biopharmaceutical company dedicated to the
discovery, development and commercialization of therapeutics to treat serious
and rare diseases. The company successfully completed an IPO in 2013.

NASDAQ: XLRN

acceleronpharma.com

Lead: Jean George

Fund: ATV

Location: Cambridge, MA

NEWS:

07.08.16
Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress
on Neuromuscular Diseases



05.16.14
Acceleron was named 'Exit of the Year' and Acceleron's John Knopf was named
'Entrepreneur of the Year - Healthcare.' at 2014 NEVY Awards



03.24.14
Acceleron, Celgene and Collaborators Announce Two Publications in Nature
Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in
Beta-thalassemia and Myelodysplastic Syndromes



X




Active | Biopharmaceuticals

Alchemab Therapeutics is using deep learning and cutting edge science to develop
novel drugs for patients with hard-to-treat diseases by harnessing the power of
naturally protective antibodies and the adaptive immune system.

alchemab.com

Lead: Jason Lettmann

Fund: LSV

Location: Cambridge, UK

NEWS:

11.15.21
Alchemab Therapeutics Appoints Young T. Kwon, PhD as Chief Financial and
Operating Officer



06.22.21
Alchemab's new well-connected CEO will lead biotech on journey to address
hard-to-treat diseases



05.05.21
AstraZeneca taps antibody-mining startup Alchemab to dig into prostate cancer



04.15.21
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for
identifying disease-modifying antibody therapeutics



X




Active | Biopharmaceuticals

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform
post-surgical pain management and recuperation for patients and physicians.

allaytx.com

Lead: Mike Carusi

Fund: LSV Singapore

Location: Menlo Park, CA and Singapore

NEWS:

05.13.21
A non-opioid pain startup believes it can top the bupivacaine market — and it's
thinking in terms of weeks, not days



X




Active | Biopharmaceuticals

ALX Oncology is a clinical-stage immuno-oncology company developing therapies
that block the CD47 checkpoint mechanism, which is exploited by cancer cells to
evade the immune system. The company successfully completed an IPO in 2020.

NASDAQ: ALXO

alxoncology.com

Lead: Jason Lettmann

Fund: LSV

Location: Dublin, Ireland

NEWS:

05.10.21
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of
ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of
Patients with Advanced Head and Neck Squamous Cell Carcinoma



03.04.21
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of
Cancer Immunotherapeutics



12.09.20
ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock



07.17.20
Immuno-oncology biotech ALX Oncology prices upsized IPO at $19, above the range



02.18.20
After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer
hopeful



02.12.20
ALX Oncology Announces Closing of $105 Million Series C Financing



06.01.19
ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial
Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors



11.07.18
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination
Cohorts for the Treatment of Patients with Advanced Solid Tumors



06.04.18
Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical
Trial in Patients with Advanced Solid Tumors and Lymphoma



12.07.17
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin
Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)



11.10.17
Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical
Trial in Patients with Advanced Solid Tumors and Lymphoma



04.10.17
Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for
the Treatment of Advanced Solid Tumors and Lymphoma



07.25.16
BioCentury Emerging Company Profile of Alexo Therapeutics



X




Active | Medical Technology

Apreo Health is a development stage medical technology company that is
developing innovative, globally applicable treatments for pulmonary disease.

thefoundry.com

Lead: Hanson S. Gifford, III

Fund: LSV

Location: Menlo Park, CA

X




Select Exits | Medical Technology

Ardian is a medical device company developing catheter-based therapies to treat
hypertension and related conditions. Ardian was incubated within The Foundry,
the premier medical technology incubator, and was acquired by Medtronic (NYSE:
MDT) in 2011.

ardian.com

Lead: Hank Plain, Mike Carusi

Fund: ATV, Morgenthaler

Location: Mountain View, CA

X




Active | Biopharmaceuticals

Atsena Therapeutics is a clinical-stage gene therapy company focused on
developing novel therapeutics to prevent or reverse blindness.

atsenatx.com

Lead: Jason Lettmann

Fund: LSV

Location: Boston, MA

NEWS:

12.16.20
Eyeing phase 3, Atsena raises $55M financing for blindness gene therapy



X




Select Exits | Biopharmaceuticals

Avidia is a biopharmaceutical company discovering and developing a new class of
human therapeutic proteins called Avimer™. The company was acquired by Amgen
(NASDAQ: AMGN) in 2006.

amgen.com

Fund: Morgenthaler

Location: Mountain View, CA

X




Select Exits | Medical Technology

Cabochon Aesthetics is a medical device company developing effective, scientific
solutions for the aesthetic treatment of cellulite. The company was incubated
within The Foundry, the premier medical technology incubator, and was acquired
by Ulthera in 2014.

Lead: Hank Plain

Fund: Morgenthaler

Location:

X




Active | Medical Technology

Cala Health is a bioelectronic medicine company transforming the standard of
care for chronic disease. Its lead product, Cala Trio™, is the only non-invasive
prescription therapy for essential tremor and is now available through a unique
digital business model of direct-to-patient solutions.

calahealth.com

Lead: Mike Carusi

Fund: LSV

Location: Burlingame, CA

NEWS:

10.03.22
Cala Health’s real-world study validates its wearable’s long-term efficacy



06.10.22
Cala Health Tackles Hand Tremors With Bioelectronic Treatment



05.23.22
SK Biopharmaceuticals partners with Cala to fuel innovation in neurology



04.04.22
New Research Presented at AAN Demonstrates Burden Associated with Essential
Tremor and the Unmet Patient Need



03.28.22
Cala Health announces new chief commercial, financial officers amid leadership
expansion



03.01.22
Cala Health Is Building Momentum By Expanding Affordable Access for Patients
with Essential Tremor



01.11.22
The Top 25 Women Leaders in Medical Devices of 2022



11.16.21
Cala Health Raises $77M to Expand Patient Access and Fuel Continued Innovation



09.14.21
Cala Health wearables shown to decrease tremor movement



07.20.21
The 18 most innovative medical devices of 2021



06.24.21
52 Women-Led Startups Driving The Future Of HealthTech And FemTech



06.18.21
Med-Tech Innovation News spoke to Renee Ryan, CEO of Cala Health, about its work
tackling chronic diseases.



06.17.21
Cala Health and University of California, San Francisco Announce Partnership to
Develop Next-Generation, Smart Neuromodulation Therapies



06.14.21
The Top 25 Women Leaders in Consumer HealthTech of 2021



06.10.21
Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee
Ryan, CEO of Cala Health



06.07.21
Cala Health Announces Expansion of Executive Team with Steve Higa and Greg
Schulte



05.20.21
Cala Health Reports New Data Presented at ISPOR, Highlighting Essential Tremor
(ET)-Related Comorbidities and Economic Burden



05.20.21
Patients With Essential Tremor Experience High Economic Burden



05.12.21
The Ultimate List of Private Medtech Companies to Watch (Updated)



04.15.21
New Data Demonstrate How Cala Trio™ Enables a More Frequent Assessment of Hand
Tremor Compared with In-Person Assessments in Patients with Essential Tremor and
Supports Feasibility of Telemedicine Approaches for Essential Tremor Management



03.13.21
7 Companies Developing Bioelectronic Devices



01.26.21
The Top 25 Women Leaders in Medical Devices of 2021



10.22.20
Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy
to Treat Action Tremors in Parkinson's Disease Read more:
http://www.digitaljournal.com/pr/4850531#ixzz6bdadGbzb



09.14.20
Cala Health’s wrist-worn stimulator improves tremor control in real-world study



07.22.20
The Galien Foundation Introduces 2020 Prix Galien USA Nominees in "Best
Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical
Technology" Categories



02.14.20
Cala Health aims to restore functionality to essential tremor patients with
wearables



01.24.20
THIS WEARABLE CAN STIMULATE NERVES TO EFFECTIVELY CANCEL OUT HAND-TREMORS… AND
IT’S A WATCH TOO.



01.09.20
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential
Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™



09.04.19
Cala Health Names Veteran Leader Renee Ryan as Chief Executive Officer



05.21.19
Cala Health raises $50M ahead of commercial launch of its bioelectric
stimulation device



02.16.16
Stealth Stanford spinout Cala Health raises $18M for wearable device that treats
hand and wrist tremors



X




Select Exits, Active | Biopharmaceuticals

Calithera Biosciences is a clinical-stage biopharmaceutical company focused on
discovering and developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of cancer. The company
successfully completed an IPO in 2014. Morgenthaler Ventures have exited the
investment since IPO.

NASDAQ: CALA

calithera.com

Lead: Jean George

Fund: ATV, Morgenthaler

Location: South San Francisco, CA

NEWS:

11.02.20
Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to
Support Clinical Development of Arginase Inhibitor, CB-280



07.13.20
Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for
the Treatment of Cystic Fibrosis



10.03.19
Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial
of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma



02.21.19
Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for
the Treatment of Cystic Fibrosis



09.07.16
Lightstone Ventures Adds Susan Molineaux as Scientific Advisor



07.25.16
Calithera Biosciences Announces FDA Acceptance of Investigational New Drug
Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune
Metabolic Checkpoint



03.25.14
Is Calithera the next biotech IPO hopeful?



X




Active | Medical Technology

Developing the next generation of percutaneous left ventricular assist devices

cardiacbooster.com

Lead: Mark Deem

Fund: LSV

Location: The Netherlands

X




Active | Biopharmaceuticals

Carrick Therapeutics is a biopharmaceutical company pioneering a portfolio of
unique, first in class cancer treatments that target driver mechanisms of the
most aggressive forms of cancer, and which will be tailored to an individual
patient’s tumour.

carricktherapeutics.com

Lead: Jason Lettmann

Fund: LSV

Location: Dublin, Ireland

NEWS:

08.02.21
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel
Samuraciclib Combination to Treat HR+ Breast Cancer



06.28.19
Carrick Therapeutics Announces Plan to Establish US Operations and Appointment
of Tim Pearson as CEO



10.11.18
Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and
Appoints George Golumbeski as Chairman



10.04.16
New Startup Carrick Therapeutics Launches With $95 Million and Taps Former
AstraZeneca PLC-Eli Lilly Exec as CEO



X




Active | Biopharmaceuticals

Catabasis Pharmaceuticals is a biopharmaceutical company dedicated to the
discovery and development of an innovative, effective and safe medicine to treat
Duchenne Muscular Dystrophy (DMD). The company successfully completed an IPO in
2015.

NASDAQ: CATB

catabasis.com

Lead: Jean George

Fund: ATV, LSV

Location: Cambridge, MA

NEWS:

06.12.20
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General
Counsel



12.16.19
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected
Patient Population



09.30.19
Catabasis Pharmaceuticals Announces The Phase 3 PolarisDMD Trial Of
Edasalonexent In Duchenne Muscular Dystrophy Has Exceeded Target Enrollment



11.27.18
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of
Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy



09.25.18
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For
Edasalonexent In Duchenne Muscular Dystrophy



10.04.17
Catabasis Pharmaceuticals Reports Positive Results From Open-Label Extension Of
Phase 2 MoveDMD® Trial Evaluating Edasalonexent In Duchenne Muscular Dystrophy
And Plans To Initiate Phase 3 Clinical Trial In First Half 2018



02.18.16
Crossing paths LINKING INFLAMMATION AND OXIDATION IN ALS



06.25.15
Catabasis Pharmaceuticals Announces Pricing Of Initial Public Offering



X




Active | Biopharmaceuticals

Catalyst Biosciences is a biopharmaceutical company developing therapeutics that
utilize protease enzymes called “Alterase™ Therapeutics.” The company completed
a reverse merger with Targacept in 2015.

Fund: Morgenthaler

Location: South San Francisco, CA

X




Active | Biopharmaceuticals

Catamaran Bio is a biopharmaceutical company developing next generation NK cell
therapy platform with a predominant focus on solid tumors. The company was
founded by SV Health Investors alongside academic founders Branden Moriarty and
Catherine Bollard.

Lead: Caroline Gaynor

Fund: LSV

Location:

NEWS:

05.16.22
Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell
Therapies For Treating Solid Tumors



04.27.22
Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer



04.05.22
Catamaran Bio Appoints Frank Lee as Chair of Its Board of Directors



03.14.22
Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the
University of Minnesota and Secures an Exclusive Patent License to Next
Generation Manufacturing Technologies



02.28.22
Catamaran Bio Announces Appointment of Michael DeRidder, PhD, as Senior Vice
President, Corporate Strategy and New Product Planning



12.13.21
Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf
CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers



11.04.21
Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data
Presentation at ASH 2021



08.02.21
Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President,
Technical Operations and Manufacturing



06.24.21
Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR‑NK Cell
Manufacturing Technologies



05.11.21
Catamaran Bio’s Scientific Founder Leads Pivotal Advancements in Non-viral
Engineering of CAR-NK Cells Using Novel Transposon Technology



04.26.21
Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer



02.04.21
Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief
Executive Officer



11.23.20
Catamaran Bio sails into the CAR-NK waters with a $42M launch round



11.23.20
Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf
CAR-NK Cell Therapies to Treat Solid Tumors



X




Active | Biopharmaceuticals

Cerevance is a biopharmaceutical company that is taking a novel approach to the
discovery and development of therapeutics for CNS and psychiatric diseases
utilizing its powerful NETSseq target discovery platform.

cerevance.com

Lead: Jason Lettmann

Fund: LSV

Location: Boston, MA

NEWS:

08.09.22
Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after
dropping the BACE



11.16.20
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition
Study



04.14.20
Gates, GV chip into $45M round for CNS biotech Cerevance



12.18.19
Takeda and Cerevance Team Up to Take on GI Diseases



04.30.19
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s
Disease Drug CVN424



03.05.19
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as
VP of Neuroscience



09.25.18
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of
Parkinson’s Disease



12.02.16
Takeda and Lightstone join forces to fund and launch neuroscience upstart



X




Select Exits | Medical Technology

Claret Medical is a medical device company developing innovative solutions for
cerebral protection during structural heart and vascular interventions. The
company was acquired by Boston Scientific (NYSE: BSX) in 2018.

claretmedical.com

Lead: Hank Plain

Fund: LSV

Location: Santa Rosa, CA

NEWS:

07.20.18
Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.



06.05.17
Claret Medical Receives FDA Clearance to Market Sentinel Cerebral Protection
System in the U.S.



02.27.17
FDA Advisory Committee Strongly Supports Granting De Novo Application For The
First Cerebral Protection System For Transcatheter Aortic Valve Replacement
(TAVR)



11.01.16
Results from U.S. Pivotal IDE Trial Show That Sentinel Cerebral Protection
System Protects Patients During Transcatheter Aortic Valve Replacement



09.20.16
CLARET MEDICAL SUBMITS MARKETING APPLICATION TO FDA FOR US CLEARANCE OF FIRST
CEREBRAL PROTECTION SYSTEM FOR TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)



09.14.16
CLARET MEDICAL ANNOUNCES SENTINEL PIVOTAL IDE TRIAL TO BE FEATURED IN
LATE-BREAKING TRIAL SESSION AT TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT)
CONFERENCE



08.29.16
Endovascular Filter Device Helps Prevent Periprocedural Stroke



10.15.15
Claret Medical Release: New Study Shows Definitive Neurocognitive Benefit For
Patients Protected By Sentinel Cerebral Protection System During Transcatheter
Aortic Valve Replacement (TAVR)



X




Active | Medical Technology

Contego Medical is a Raleigh-based medical device company developing a suite of
products for the treatment of neurovascular, coronary and peripheral vascular
disease.

contegomedical.com

Lead: Hanson S. Gifford, III

Fund: LSV

Location: Raleigh, NC

NEWS:

04.13.22
Raleigh medical device company Contego Medical raises more than $15M



04.16.21
Contego Medical Receives CE Mark Approval for Next Generation Carotid Stent



06.15.20
Contego Medical Announces the Start of Enrollment in the PERFORMANCE II Carotid
Stenting Clinical Trial



X




Active | Biopharmaceuticals

Cyteir Therapeutics is a biopharmaceutical company and a leader in the discovery
and development of novel therapeutics based on the biology of DNA repair and
synthetic lethality for the treatment of cancer and autoimmune diseases. The
company successfully completed an IPO in 2021.

NASDAQ: CYT

cyteir.com

Lead: Jean George

Fund: LSV

Location: Cambridge, MA

NEWS:

06.05.22
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and
Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic
Malignancies



02.08.22
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851



02.07.22
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of
Directors



01.12.22
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial
With CYT-0851



12.16.21
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to
Board of Directors



09.20.21
Cyteir Therapeutics Selected to Join Russell 2000® Index



06.17.21
Cyteir Therapeutics Announces Pricing of Initial Public Offering



06.15.21
Cyteir Therapeutics Aims For $126 Million IPO



06.05.21
Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of
CYT-0851



05.28.21
Oncology biotech Cyteir Therapeutics files for a $100 million IPO



02.11.21
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance
Clinical Trials of Lead RAD51 Program



07.07.20
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality
Program in Cancer and Expands Senior Leadership Team



10.15.19
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing
and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor



03.31.19
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is
Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors



03.08.18
Bound for the clinic with a new approach to synthetic lethality, Cyteir bags
$29M



03.08.18
Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases



X




Active | Biopharmaceuticals

Disarm® Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company, is
pursuing a promising new class of potential therapeutics called SARM1 inhibitors
that target axonal degeneration as a treatment for amyotrophic lateral sclerosis
(ALS – Lou Gehrig’s Disease), multiple sclerosis, peripheral neuropathies –
which cause weakness and pain in the feet and hands – and other debilitating
neurological disorders.

lilly.com/discovery/research-and-scientific-discovery/disarm-therapeutics

Lead: Jean George

Fund: LSV

Location: Cambridge, MA

NEWS:

10.15.20
Lilly Announces Agreement to Acquire Disarm Therapeutics



01.13.20
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief
Financial Officer



10.22.19
Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1
Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo



11.03.18
Disarm Therapeutics Presents New Data Validating Role of SARM1 in Axonal
Degeneration



X




Active | Medical Technology

EarLens is a medical device company developing next generation hearing
technology that uses light to transmit sound and energy directly to the eardrum
enabling users to appreciate high frequency sounds and improved speech
recognition, especially in noisy environments.

earlens.com

Lead: Hank Plain

Fund: LSV

Location: Redwood City, CA

NEWS:

09.06.22
Earlens Shares FDA Historical Ruling on OTC Hearing Aids



05.06.22
New device aims to provide better sound than hearing aids



12.15.21
Earlens Wins "Best CEO" Award



09.10.21
New device for hearing loss acts like a contact lens for the ear



07.14.21
Earlens wins "Best Leadership Team" and "Best CEOs for Diversity" awards



05.13.21
Study demonstrates significant listening advantages with Earlens hearing
technology



05.12.21
The Ultimate List of Private Medtech Companies to Watch (Updated)



03.18.20
Earlens Wins Gold 2020 Edison Award for its Revolutionary Earlens® Contact
Hearing Solution



01.13.20
Earlens inks new partnership with Verily



04.08.19
Tackling the Burden and Shame of Hearing Loss



03.14.17
Comparison of Real-world Bandwidth in Hearing Aids vs Earlens Light-driven
Hearing Aid System



09.06.16
Earlens Selects iBASEt to Support 3D Printing of Revolutionary Hearing Aid



06.16.16
Earlens raises $51M to launch laser-based hearing aid after FDA nod



01.19.16
EarLens hearing aid uses laser light to transmit sound



09.29.15
FDA Permits Marketing Of New Laser-Based Hearing Aid With Potential For Broad
Sound Amplification



X




Active | Biopharmaceuticals

Elcelyx Therapeutics is a biopharmaceutical company developing therapeutic
agents based on the finding that modulation of the neuro-enteroendocrine system
of the gut, including L-cells, amplifies the release of hormones such as those
that play an important role in glucose regulation.

elcelyx.com

Fund: Morgenthaler

Location: San Diego, CA

X




Active | Medical Technology

EndoGastric Solutions is a medical device company developing and commercializing
innovative, evidence-based and incisionless surgical technology for the
treatment of GERD.

endogastricsolutions.com

Lead: Mike Carusi

Fund: ATV

Location: Redwood City, CA / Redmond, WA

NEWS:

11.14.17
EndoGastric® Solutions Announces Further Expansion of Medicare Reimbursement for
Transoral Incisionless Fundoplication (TIF®) 2.0 Procedure



10.18.16
Durable Treatment Of GERD With TIF 2.0: A Surgical Products Q&A



09.26.16
EndoGastric Solutions Announces Publication of Long-Term Data Demonstrating TIF®
2.0 Procedure Offers Durable Treatment of Chronic GERD



08.24.16
Device treats severe heartburn at the source



07.05.16
EndoGastric Solutions touts U.S. reimbursement win



05.12.16
FDA Clears Next-Generation Version of EndoGastric Solutions’ EsophyX® Device



12.01.15
EndoGastric Solutions gets $50M for “natural orifice” device to treat GERD



10.15.15
EndoGastric Solutions Announces New Sham-Controlled European Study Demonstrates
Transoral Incisionless Fundoplication (TIF) Procedure as Effective Alternative
for Daily PPI Treatment



09.09.15
EndoGastric Solutions Announces AMA Assignment of CPT Code and Short Form
Descriptor



04.17.15
EndoGastric skips toward positive study review for GERD device



03.12.15
GERD Device Maker Uses Clinical Data to Prove Its Point



01.22.15
GERD transoral surgical startup releases sham-controlled data as it awaits
reimbursement code



01.21.15
EndoGastric Solutions Announces Publication of Landmark Data in Gastroenterology
Demonstrating Superiority of Transoral Incisionless Fundoplication For Treatment
of Troublesome Regurgitation



05.01.14
EndoGastric Solutions Names Industry Veteran Skip Baldino CEO



X




Active | Medical Technology

FIRE1 is a medical device company developing novel remote monitoring devices to
improve patient quality of life and outcomes while lowering overall healthcare
costs.

fire1foundry.com

Lead: Jason Lettmann

Fund: LSV

Location: Dublin, Ireland

NEWS:

01.30.18
FIRE1 raises $50M to develop remote heart monitoring device



04.22.16
Exits and IPOs the best medicine for Ireland’s medtech hub (video)



04.12.16
FIRE1 Closes Series B Financing, Announces New CEO



04.12.16
Medtronic backs stealthy Foundry startup as it nabs $7.5M for novel remote
patient monitoring



X




Select Exits | Biopharmaceuticals

FivePrime Therapeutics is a biopharmaceutical company focused on the discovery
and development of a complete range of innovative protein and antibody drugs.
The company successfully completed an IPO in 2013.

(NASDAQ: FPRX)

fiveprime.com

Lead: Jean George

Fund: ATV

Location: Boston, MA

NEWS:

10.15.15
Five Prime, Bristol Shake Hands Again in New $350M Cancer Pact



03.17.14
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to
Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways



X




Select Exits | Biopharmaceuticals

Flex Pharma is a biopharmaceutical company dedicated to creating innovative,
novel treatments for neuromuscular disorders, and has demonstrated initial human
efficacy related to muscle cramping. The company successfully completed an IPO
in 2015.

NASDAQ: FLKS

flex-pharma.com

Lead: Jean George

Fund: LSV

Location: Boston, MA

NEWS:

12.15.15
Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist



01.28.15
Flex Pharma Announces Pricing Of Initial Public Offering



X




Select Exits | Biopharmaceuticals

FoldRx Pharmaceuticals is a biopharmaceutical company developing disease
modifying drug therapies for diseases of protein misfolding and amyloidosis. The
company was acquired by Pfizer (NYSE: PFE) in 2010.

Fund: Morgenthaler

Location: Cambridge, MA

X




Select Exits | Medical Technology

ForSight VISION2 is a medical device company that developed a proprietary ocular
punctal plug drug delivery system. The company was acquired by QLT Inc. (NASDAQ:
QLTI) in 2007.

Fund: Morgenthaler

Location: Menlo Park, CA

X




Select Exits | Medical Technology

ForSight VISION4 is a medical device company developing novel drug delivery
therapies for the treatment of retinal diseases.  The company was incubated
within ForSight Labs and was acquired by Roche (OTCQX: RHHBY) in 2017.

Fund: Morgenthaler

Location: Menlo Park, CA

X




Select Exits | Medical Technology

ForSight VISION5 is a medical device company focused on a novel anterior segment
drug delivery program for ophthalmic drugs. The company was incubated within
ForSight Labs and was acquired by Allergan (NYSE: AGN) in 2016.

Fund: Morgenthaler

Location: Menlo Park, CA

X




Active | Biopharmaceuticals

Gemini Therapeutics is a precision medicine company developing a broad,
multimodal pipeline of first-in-class therapeutics for genetically-defined
age-related macular degeneration and rare diseases.

geminitherapeutics.com

Lead: Jean George

Fund: LSV Singapore, LSV

Location: Cambridge, MA

NEWS:

08.10.22
Gemini Therapeutics and Disc Medicine Announce Merger Agreement



08.30.21
Gemini Therapeutics Announces Presentation of Previously Released Data from Its
Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit



05.03.21
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of
Board of Directors



04.12.21
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer



02.10.21
Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry
Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic
Variants



02.09.21
Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer



02.08.21
Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused
on Age-Related Macular Degeneration



02.01.21
Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On
to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for
Progressive Vision Loss Due to Macular Atrophy



01.07.21
Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for
the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients With
Complement Factor H (CFH) Loss of Function Gene Variants



10.15.20
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating
Publicly Listed Precision Medicine Company Focused on Age-Related Macular
Degeneration



10.15.20
Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip



05.07.20
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer



04.28.20
Gemini Therapeutics Appoints David Lubner as Independent Director



02.26.20
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research
Collaboration to Explore New Targets for Age-related Macular Degeneration



01.09.20
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry
Age-related Macular Degeneration



09.13.19
Gemini Therapeutics Announces Leadership Appointment



01.07.19
Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and
Natural History Study of Subjects with Dry AMD and High-Risk Genotypes



10.17.17
Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision
med to AMD



X




Select Exits | Medical Technology

GI Dynamics is a medical device company developing a device to treat metabolic
disease with gastric bypass. The company successfully completed an IPO on the
Australian Securities Exchange in 2011.

ASX: GID

gidynamics.com

Fund: ATV

Location: Lexington, MA

NEWS:

03.23.16
GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott
Schorer as President & Chief Executive Officer



X




Active | Medical Technology

Gynesonics is a medical device company focused on advancing women’s health by
developing minimally invasive, transcervical, uterus-preserving and
incision-free technologies for diagnostic and therapeutic applications.

gynesonics.com/us

Lead: Mike Carusi

Fund: ATV

Location: Redwood City, CA

NEWS:

06.03.21
Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for
Treatment of Uterine Fibroids with the Sonata System



06.01.21
New Guidance from the American College of Obstetricians and Gynecologists for
Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation
as a Uterus-Preserving Treatment Option



04.15.21
Gynesonics Announces Publication of SAGE Global Registry Preliminary Results:
Real-World Usage Corroborates the Safety and Applicability of Sonata
Transcervical Fibroid Ablation



04.08.21
Gynesonics Announces Publication of Clinical Study Analysis Demonstrating
Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic
Uterine Fibroids



03.18.21
Gynesonics Appoints Susan Stimson to Its Board of Directors



03.09.21
Gynesonics Announces Centers for Medicare and Medicaid Services Final Rule
Approves Ambulatory Surgery Centers as a Site of Service for Transcervical
Uterine Fibroid Ablation with Device Intensive Designation



01.21.21
Gynesonics Announces That Detroit Medical Center Huron Valley-Sinai Hospital has
Introduced Sonata, A New Innovative, Incision-Free Treatment for Symptomatic
Uterine Fibroids



01.12.21
Runway Growth Capital Announces a Senior Secured Term Loan of $50 Million to
Gynesonics



07.22.15
Gynesonics gets $43M to back pivotal trial of uterine fibroid ablation device



04.22.14
Gynesonics Names Christopher M. Owens President, Chief Executive Officer



X




Select Exits | Biopharmaceuticals

Hypnion is a biopharmaceutical company developing novel therapeutics for the
treatment of central nervous system disorders such as sleep, wake-alertness
disorders and circadian rhythm abnormalities. The company was acquired by Eli
Lilly (NYSE: LLY) in 2007.

Lead: Jean George

Fund: ATV

Location: Lexington, MA

X




Active | Biopharmaceuticals

Ligature is an early stage biopharmaceutical company focused on the research and
development of small molecule drugs designed to degrade undruggable
disease-causing proteins with precision, delivering new therapies for
intractable cancers.

ligaturetx.com

Lead: Kenneth D. Noonan, Ph.D., Wen Qi Ho, Ph.D.

Fund: LSV Singapore

Location: Singapore

NEWS:

01.04.21
Ligature Therapeutics Launches, Raises USD $6M in Seed Financing



01.04.21
EXPERIMENTAL DRUG DEVELOPMENT CENTRE LAUNCHES SPIN-OFF TO DEVELOP TARGETED
PROTEIN DEGRADERS FOR TREATING INTRACTABLE DISEASES



X




Active | Biopharmaceuticals

Locanabio is an RNA-targeting gene therapy company with a platform technology to
address a wide spectrum of human genetic diseases.

locanabio.com

Lead: Jean George

Fund: LSV Singapore, LSV

Location: San Diego, CA

NEWS:

05.23.22
Gene Therapy Lowers Toxic RNA Due to C9ORF72 Mutations in ALS



09.07.21
Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief
Financial Officer



07.06.21
Locanabio Expands Leadership Team with Appointment of Chief Scientific Officer
and Chief Medical Officer



05.05.21
Locanabio Announces Upcoming Preclinical Data Presentations at American Society
of Gene and Cell Therapy Annual Meeting



12.14.20
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of
Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and
Retinal Diseases



04.01.20
Locana Expands Leadership Team with Appointment of Micah Mackison, as Chief
Business Officer



12.10.19
Locana Expands Leadership Team with Appointment of former Casebia CEO, James
Burns, Ph.D., as Chief Executive Officer



06.21.19
Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA



06.12.19
MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for
Muscular Dystrophy



10.05.17
Arming Bodies with CRISPR to Fight Huntington’s Disease and ALS



X




Active | Biopharmaceuticals

MediSix Therapeutics is an early-stage cell therapy company that is taking a
novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T
cell lymphoma and leukemia.

medisixtx.com

Lead: Kenneth D. Noonan, Ph.D., Mike Carusi

Fund: LSV Singapore

Location: Boston, MA and Singapore

NEWS:

05.14.18
MediSix Therapeutics Launches with USD$20M Series A Financing



09.11.17
MediSix Therapeutics Signs Exclusive Licensing Agreement with the National
University of Singapore



X




Select Exits | Medical Technology

MicroVention is a medical device company developing and marketing innovative
neuroendovascular technologies for the treatment of vascular diseases in small
vessels.  The company was acquired by Terumo (TYO: 4543) in 2006.

microvention.com

Lead: Mike Carusi

Fund: ATV

Location: Tustin, CA

X




Select Exits | Biopharmaceuticals

Morphotek is a biopharmaceutical company developing novel classes of
biological-based products to treat cancer, inflammation and infectious diseases.
The company was acquired by Eisai Inc. (TYO: 4523) in 2007.

Fund: Morgenthaler

Location: Exton, PA

X




Active | Biopharmaceuticals

Mosaic Biosciences is a biotechnology company that is advancing a highly
versatile and fundamentally new class of biomaterials based on engineered
proteins and synthetic polymers.

mosaicbio.com

Fund: Morgenthaler

Location: Boulder, CO

X




Active | Medical Technology

Moximed is a medical device company that is developing innovative devices for
patients with osteoarthritis of the knee. The company was incubated within the
ExploraMed incubator.

moximed.com

Fund: Morgenthaler

Location: Hayward, CA

NEWS:

03.16.17
Moximed Closes Oversubscribed $50MM Financing Round



03.16.17
Moximed closes $50m Series C



05.09.16
Moximed’s AtlasTM Knee System Improves Pain Scores and Returns Function to
Pre-Arthroplasty Patients with Medial Knee Osteoarthritis



12.14.15
CE Mark in hand, Moximed hatches U.S. approval strategy for knee stabilization
implant



11.18.15
Moximed Announces CE Mark and First Commercial Use of AtlasTM Knee System



05.07.15
Moximed Closes $33MM Financing Round



X




Select Exits, Active | Biopharmaceuticals

Nimbus Therapeutics is a biotechnology company focused on designing highly
selective and potent medicines to disrupt known drivers of serious diseases. The
company was formed using an LLC model. Its lead program was acquired by Gilead
Sciences (NASDAQ: GILD) in 2016.

nimbustx.com

Lead: Jean George

Fund: LSV

Location: Cambridge, MA

NEWS:

10.11.22
Nimbus Therapeutics Announces Research Collaboration and License Agreement with
Lilly for Small Molecule Activators of AMPK



01.06.22
Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor
Program and Provides Additional Business Updates



07.13.21
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline
Including Multiple Clinical Programs



10.14.20
Nimbus Therapeutics Announces $60 Million Private Financing From New Investors
to Advance Expanded Pipeline



06.22.20
Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust
Inhibition of Tumor Growth In Vivo



06.08.20
Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across
Oncology, Immunology and Metabolism



06.08.20
Nimbus CEO Keiper: 'We're not just a one-hit wonder'



05.15.20
Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1
Inhibitor With Robust In Vivo Activity



12.17.19
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to
President of the Company’s Tyk2 Subsidiary



10.03.17
Celgene pens pact to join Bristol-Myers, Pfizer in R&D race



04.21.17
Gilead says first data on Nimbus NASH candidate are positive



04.05.17
Nimbus in full-on drug development partnership with Charles River



11.01.16
Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into
PhII NASH trial



11.01.16
Nimbus Therapeutics Announces $200 Million Milestone Payment from Gilead
Sciences for Allosteric ACC Inhibitor Program in Non-alcoholic Steatohepatitis
(NASH)



10.20.15
Nimbus Therapeutics Announces Global License Agreement with Genentech



03.18.15
Pfizer joins a powerhouse syndicate backing $43M round for Nimbus



X




Active | Medical Technology

Nuvaira is a medical device company developing novel devices for treating
obstructive lung diseases. The company was incubated within The Foundry, the
premier medical technology incubator.

nuvaira.com

Lead: Mike Carusi, Hank Plain

Fund: LSV, ATV, Morgenthaler

Location: Minneapolis, MN

NEWS:

03.05.21
Targeted Lung Denervation Found Effective, Safe Over 3 Years of Follow-up



06.08.20
Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial
Device



02.04.20
Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone



02.11.19
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking
Treatment of COPD



09.05.16
Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in
Obstructive Lung Disease at ERS



08.03.16
First COPD Patient Treated in Holaira's Sham Controlled Trial of Targeted Lung
Denervation



10.07.14
Holaira Announces First Patient Treatment in Randomized Study of Targeted Lung
Denervation for COPD



04.03.14
Plymouth-based Holaira raises $42 million



X




Select Exits | Biopharmaceuticals

Orexigen Therapeutics is a biopharmaceutical company developing therapies for
the treatment of obesity. The company successfully completed an IPO in 2007.

NASDAQ: OREX

nalpropion.com

Fund: Morgenthaler

Location: La Jolla, CA

X




Active | Biopharmaceuticals

A NewCo focused on developing novel autoimmune therapies.

Lead: Caroline Gaynor

Fund: LSV

Location: Dublin, Ireland

X




Select Exits | Biopharmaceuticals

Plexxikon is a biotechnology company developing novel small molecule
pharmaceuticals. The company has utilized its proprietary discovery platform to
develop a portfolio of competitively differentiated therapeutic programs. The
company was acquired by Daiichi Sankyo (TYO: 4568) in 2011.

plexxikon.com

Lead: Mike Carusi

Fund: ATV

Location: Berkley, CA

X




Select Exits | Biopharmaceuticals

Portola Pharmaceuticals is a biopharmaceutical company developing innovative
therapeutics for cardiovascular and autoimmune/inflammatory diseases. The
company successfully completed an IPO in 2013.

NASDAQ: PTLA

portola.com

Lead: Jean George

Fund: ATV

Location: South San Francisco, CA

X




Select Exits | Medical Technology

PowerVision is a medical device company developing a proprietary
fluid-controlled accommodating intraocular lens (IOL) technology to restore the
vision of youth to millions of middle-aged or elderly individuals. The company
was acquired by Alcon (NYSE: ALC) in 2019.

powervisionlens.com

Lead: Mike Carusi

Fund: ATV

Location: Belmont, CA

NEWS:

03.18.19
Alcon Announces Acquisition of PowerVision, Inc.



03.18.19
Alcon Acquires PowerVision for $285 Million



01.23.17
PowerVision - FierceMedicalDevices' 2016 Fierce 15



05.18.16
Barry Cheskin, CEO, president and co-founder of PowerVision, provides details on
his company’s new partnership with Alcon.



04.21.16
Novartis' Alcon Partners With Eye Device Startup PowerVision



12.10.15
ACCOMMODATIVE IOL PROVIDES GOOD VISUAL ACUITY



03.01.15
A Fluid-Based Accommodating IOL



X




Select Exits | Biopharmaceuticals

Principia Biopharma is a biopharmaceutical company developing novel compounds
with enhanced sensitivity, high potency and longer duration of effect. Principia
was acquired by Sanofi (NASDAQ: SNY) in 2020.

principiabio.com

Fund: Morgenthaler

Location: Menlo Park, CA

X




Select Exits | Biopharmaceuticals

Promedior is a clinical stage biotechnology company pioneering the development
of targeted therapeutics to treat diseases involving fibrosis. The company was
acquired by Roche Holding (OTCMKTS: RHHBY) in 2019.

promedior.com

Lead: Jason Lettmann

Fund: Morgenthaler

Location: Lexington, MA

NEWS:

12.10.15
Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH
Annual Meeting



08.31.15
Bristol-Myers forges $1.25B deal to beef up fibrosis pipeline in Promedior
buyout



X




Select Exits | Biopharmaceuticals

Proteolix is a biopharmaceutical company developing novel therapies that target
the proteasome for the treatment of hematological malignancies and solid tumors.
The company was acquired by Onyx Pharmaceuticals (NASDAQ: ONXX) in 2009.

onyx.com

Lead: Jean George

Fund: ATV

Location: South San Francisco, CA

X




Active | Medical Technology

Proverum is an Irish medical device company founded in 2016 as a spin-off from
Trinity College Dublin. The company is developing a novel treatment solution for
patients with symptomatic BPH designed to be safely and effectively performed in
a doctor’s office setting in a simple procedure under local anaesthesia. LSV
invested in 2022 to support the Company through its pivotal trial and pursuit of
regulatory approval for the ProVee system in Europe and the US.

proverummedical.com

Lead: Caroline Gaynor

Fund: LSV

Location: Dublin, Ireland

NEWS:

06.13.22
ProVerum: First Enrolment in the ProVIDE Clinical Study for BPH Treatment



X




Select Exits | Biopharmaceuticals

Ra Pharmaceuticals is a clinical-stage biopharmaceutical company developing a
new class of drugs with the specificity of antibodies and the oral
bioavailability of small molecules. The company successfully completed an IPO in
2016.

NASDAQ: RARX

rapharma.com

Lead: Jason Lettmann, Doug Treco, Ph.D.

Fund: Morgenthaler, LSV

Location: Cambridge, MA

NEWS:

02.28.19
Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global
Movement to Raise Awareness for Rare Diseases



11.17.16
Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for
RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria



10.26.16
Ra Pharmaceuticals Announces Pricing of Initial Public Offering



10.03.16
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue



07.23.15
Ra Pharmaceuticals Announces $58.5M Series B Financing



X




Active | Medical Technology

Relievant Medsystems is a medical device company developing a new, minimally
invasive technology that targets the source of chronic low back pain with a
simple one-hour treatment.

relievant.com

Lead: Jason Lettmann

Fund: Morgenthaler, LSV

Location: Redwood City, CA

NEWS:

06.13.22
NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic
Vertebrogenic Low Back Pain



01.03.22
Relievant Medsystems’ Intracept receives new CPT codes to aid reimbursement
efforts



05.12.21
The Ultimate List of Private Medtech Companies to Watch (Updated)



05.10.21
Relievant Medsystems Names Tyler Binney President and CEO



10.29.20
Relievant Medsystems Announces $70M Financing to Accelerate U.S.
Commercialization of Intracept Procedure



10.11.16
Relievant Medsystems raises $36m



07.21.16
Relievant Medsystems wins FDA clearance for Intracept ablation device for low
back pain



X




Active | Medical Technology

Reprieve Cardiovascular is a medical device company focused on automated fluid
management technologies for acute heart failure treatment.

reprievecardio.com

Lead: Hanson S. Gifford, III

Fund: LSV

Location: Milford, MA

X




Select Exits | Biopharmaceuticals

Scioderm is a clinical-stage biopharmaceutical company developing innovative
therapies to address diseases with high unmet need, including rare diseases. The
company was acquired by Amicus Therapeutics (NASDAQ: FOLD) in 2015.

Fund: Morgenthaler

Location: Durham, NC

NEWS:

08.31.15
Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.



X




Active | Biopharmaceuticals

Second Genome is a clinical-stage biopharmaceutical company focused on
discovering and developing therapeutics identified using microbiome science.

secondgenome.com

Lead: Mike Carusi, Jason Lettmann

Fund: Morgenthaler, ATV

Location: San Bruno, CA

NEWS:

04.06.20
Second Genome signs Gilead deal in IBD, biomarkers worth up to $1.5B-plus



10.11.16
Second Genome Partners with King's College London to Evaluate the Influence of
the Microbiome in Landmark EAT Study



09.06.16
Monsanto Collaborates with Second Genome to use Microbiome Technology Platform
to Accelerate Protein Discovery



08.24.16
Second Genome’s new CEO looks to neighboring Genentech as a model for pioneering
a new field



04.20.16
Pfizer, Roche Embrace The Microbiome, Leading $43M Bet On Second Genome



02.09.16
Unraveling the Mysterious Function of the Microbiome



06.19.15
Medicine’s next frontier: The microbiome (Second Genome featured)



03.18.15
Evotec pairs up with Second Genome to gut out some R&D



01.12.15
Second Genome Advances Lead Microbiome Drug Development Program in Phase I
Clinical Trial as a Treatment for Inflammatory Bowel Disease



01.07.15
What’s Lurking In Your Microbiome? Possibly, A Cure For Disease



06.24.14
Human microbiome: Boon or boondoggle for drugmakers?



05.02.14
Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal



X




Active | Medical Technology

SetPoint Medical is a clinical-stage bioelectronic medicine company dedicated to
treating patients with chronic autoimmune diseases.

setpointmedical.com

Lead: Hank Plain

Fund: Morgenthaler

Location: Valencia, CA

NEWS:

03.13.21
7 Companies Developing Bioelectronic Devices



02.02.21
SetPoint Medical enrols first patient in study of bioelectronic platform



01.27.21
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal
Trial for its Novel Bioelectronic Platform



10.19.16
SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease



07.04.16
Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly
Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production



X




Active | Medical Technology

Shoulder Innovations, Inc. is a medical device company developing and
commercializing an innovative shoulder replacement system which addresses the
greatest cause of surgical failure: glenoid loosening. This improved system is
expected to improve patient outcomes and reduce overall system costs.

shoulderinnovations.com

Lead: Mike Carusi

Fund: LSV

Location: Holland, MI

NEWS:

03.14.22
Shoulder Innovations Announces FDA Clearance of New InSet™ Stemless Humeral
Implant



09.16.21
Reverse Shoulder Implant Reduces Glenoid Micro-Motion



08.31.21
Shoulder Innovations Relocates Corporate Headquarters



05.10.21
Shoulder Innovations Announces Exclusive License Agreement for Genesis Software
Innovations PreView Shoulder™ Software



11.02.20
Shoulder Innovations Announces Equity Financing of $21.6M



X




Active | Medical Technology

Spine Wave is a medical device company developing and marketing novel devices
for spine surgery, specifically spinal fusion, vertebral compression fracture
repair and nucleus replacement and augmentation.

spinewave.com

Fund: Morgenthaler

Location: Shelton, CT

X




Active | Biopharmaceuticals

Tallac Therapeutics is a biopharmaceutical company focused on the research and
development of CpG-Antibody conjugates intended to stimulate the immune system
in the treatment of cancer.

tallactherapeutics.com

Lead: Mike Carusi

Fund: LSV

Location: Burlingame, CA

NEWS:

07.28.22
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class
Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for
Patients with Advanced Solid Tumors



05.19.22
Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND)
Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist
Antibody Conjugate for Patients with Advanced Solid Tumors



04.15.21
Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer



04.10.21
Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody
Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American
Association for Cancer Research (AACR)



03.04.21
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of
Cancer Immunotherapeutics



12.01.20
How a Peninsula startup with a fresh $62M round wants to get cancer to pay a
toll



12.01.20
Tallac Therapeutics launches with $62M run by ALX Oncology vets, with an eye on
next-gen cancer



X




Select Exits | Biopharmaceuticals

Threshold Pharmaceuticals is a biotechnology company developing therapeutics
based on tumor hypoxia, a platform that offers potential to treat most solid
tumors. The company successfully completed an IPO in 2005.

NASDAQ: THLD

Fund: Morgenthaler

Location: South San Francisco, CA

X




Active | Biopharmaceuticals

Tizona Therapeutics is a clinical-stage immunotherapy company harnessing the
power of the immune system to develop treatments for cancer.

tizonatx.com

Lead: Jean George

Fund: LSV

Location: South San Francisco, CA

NEWS:

07.21.20
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300
Million



07.21.20
Gilead adds to string of cancer drug deals with Tizona stake



06.25.20
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers



01.03.19
AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop
First-in-Class Immunotherapy for Cancer Targeting CD39



03.09.16
Tizona signals full court press against regulatory T cells with $43M series B



03.08.16
With $70M in VC cash, Tizona takes a fresh approach to immuno-oncology



03.08.16
TIZONA THERAPEUTICS, INC., COMPLETES $43 MILLION SERIES B FINANCING



X




Active | Biopharmaceuticals

Tragara Pharmaceuticals is a biopharmaceutical company developing proprietary
drugs for the treatment of various cancers.

Fund: Morgenthaler

Location: San Diego, CA

X




Select Exits | Medical Technology

Transcend Medical is a medical device company focused on the development of
devices for the treatment of glaucoma, the leading cause of adult irreversible
blindness.  The company was acquired by Alcon (Novartis) (NYSE: NVS) in 2016.

Fund: Morgenthaler

Location: Menlo Park, CA

X




Active | Biopharmaceuticals

Trotana Therapeutics is a San Diego based biotech company dedicated to the
discovery and development of medicines targeting RNA binding proteins.

trotana.com

Lead: Jean George

Fund: LSV

Location: San Diego, CA

X




Select Exits | Medical Technology

Twelve is a medical device company developing a novel device for the treatment
of chronic cardiovascular disease.  The company was incubated within The
Foundry, the premier medical technology incubator, and was acquired by Medtronic
(NYSE: MDT) in 2015.

Lead: Hank Plain

Fund: Morgenthaler

Location: Menlo Park, CA

NEWS:

08.25.15
Medtronic to buy Twelve for $408M+, joining Abbott and Edwards on the
transcatheter mitral valve bandwagon



X




Select Exits | Medical Technology

Vapotherm is a medical device company pioneering Hi-VNI technology, a less
invasive form of support for patients in respiratory distress. The company
successfully completed an IPO in 2018.

NASDAQ: VAPO

vapotherm.com

Lead: Jason Lettmann

Fund: Morgenthaler

Location: Exeter, NH

X




Select Exits | Biopharmaceuticals

Verastem is a biopharmaceutical company bringing breakthroughs in cancer stem
cell research into new medicines for the treatment of major cancers, such as
breast cancer. The company successfully completed an IPO in 2012.

NASDAQ: VSTM

verastem.com

Lead: Jean George

Fund: ATV

Location: Cambridge, MA

NEWS:

12.15.15
Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist



X




Active | Biopharmaceuticals

Vigil Neuroscience is the world’s first microglia-focused therapeutics company.
Vigil’s purpose is clear: to treat rare and common neurodegenerative diseases by
restoring the vigilance of the microglia, the sentinel cells of the brain’s
immune system. Vigil is utilizing modern neuroscience drug development across
multiple therapeutic modalities to deliver precision-based therapies to improve
the lives of patients and their families.

vigilneuro.com

Lead: Christina Isacson, Ph.D.

Fund: LSV

Location: Cambridge, MA

NEWS:

08.12.22
Vigil Neuroscience Announces $75 Million Private Placement Financing



07.28.22
Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne
Bruhn, Ph.D.



06.07.22
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia



04.20.22
Vigil Neuroscience Expands Leadership Team and Board of Directors



01.07.22
Vigil Neuroscience Announces Pricing of Initial Public Offering



08.18.21
Vigil Neuroscience Completes $90 million Series B Financing to Advance a
Pipeline of Microglia-targeted Medicines to Treat Rare and Common
Neurodegenerative Diseases



08.18.21
Vigil raises $90M in neuroscience 'renaissance.' Is an IPO around the corner?



X




Active | Medical Technology

Willow is a medical device company commercializing a wearable breast pump that
allows women to achieve their breastfeeding goals without pressing pause on
their own lives. The company, formerly known as NC7, was incubated within
ExploraMed.

shop.willowpump.com

Lead: Mike Carusi

Fund: LSV

Location: Mountain View, CA

NEWS:

04.05.22
Willow Innovations, Inc. Launches "Register for More" Campaign; Enlists Comedian
and New Mom Iliza Shlesinger to Create its First TV Ad



03.29.22
Willow® Expands Product Suite and Unveils Willow Go™, Its Fully In-Bra Wearable
Breast Pump for Only $329



10.19.21
Willow® Introduces the Perfect Pumping Bra to Give Moms Ultimate Support When
Pumping with Willow



08.26.21
Willow Pump CEO Laura Chambers Wants to Bring Dignity Back to Breastfeeding



07.21.21
Going for the Liquid Gold: Willow Sends Breast Pumps to Olympic Athletes



06.14.21
The Top 25 Women Leaders in Consumer HealthTech of 2021



06.02.21
Willow® Launches New Sizing Inserts To Reach More Moms



04.22.21
Breast pump innovator Willow gets additional $26.8 million in funding



02.03.21
Willow Gears Up for Massive Growth In 2021 with Three Strategic Hires



11.17.20
Willow® Partners with The Motherly Shop to Expand Its DTC Offerings



09.22.20
Willow, the startup making the wearable breast pump, raises $55 million



07.10.20
Breast pump startup Willow's new CEO, Laura Chambers, on innovation for women
and mothers



06.16.20
How Airbnb exec Laura Chambers landed her first CEO job at femtech startup
Willow just as the pandemic hit



05.19.20
An ER doctor who's a new mother shares what it's like to pump milk at work while
risking exposure to coronavirus



05.18.20
Willow® Partners with Aeroflow Breastpumps to Offer Its Life-Changing Wearable
Breast Pump Through Insurance



01.10.20
Willow's hidden breast pump changed my life at CES



01.10.20
Willow is about to launch its smartest breast pump yet—and it promises more milk
+ comfort



01.05.20
Willow’s Newest Pump Promises To Be Quiet & Efficient — First Look



11.05.19
Mom Breast Pumps While Running the New York City Marathon: 'Anything Is
Possible'



01.06.19
Willow unveils a new version of its smart breast pump



11.16.17
Willow Named TIME Magazine 2017 Best Inventions



09.27.17
One Tech Company’s Revolutionary Idea: Design For Mothers First



01.05.17
The Willow could be the iPhone of breast pumps



01.05.17
Willow's smart breast pumps slide into moms' bras



01.04.17
Willow breast pump is the hands-free wearable that mothers really need



X




Select Exits | Medical Technology

ZELTIQ is a medical device company developing and marketing a non-invasive,
office-based procedure that uses Cryolipolysis, a proprietary cooling
technology, to eliminate fat. The company successfully completed an IPO in 2011.

NASDAQ: ZLTQ

coolsculpting.com

Lead: Jean George

Fund: ATV

Location: Pleasanton, CA

A COMMON PASSION FOR UNCOMMON DISCOVERIES


LIGHTSTONE TEAM



We are a group of like-minded people who live by collaboration and by
integrating business and science into breakthrough companies that can change the
lives of patients.

All Sectors Biopharmaceuticals Medical Technology

--------------------------------------------------------------------------------

All Locations Menlo Park Boston Dublin Singapore

Mike Carusi

General Partner

Jean George

General Partner

Jason Lettmann

General Partner

Hank Plain

Special Partner

Hanson S. Gifford, III

Partner

Christina Isacson, Ph.D.

Partner

Mark Deem

Operating Partner

Stacy Enxing Seng

Operating Partner

Brendan Kelly, Ph.D.

Vice President

Young Kwon, Ph.D.

Advisor

Kenneth D. Noonan, Ph.D.

CEO Lightstone Singapore PTE. LTD.

Travis Boettner

CFO & CCO

Stephanie White

Controller

Caroline Gaynor

Principal

Wen Qi Ho, Ph.D.

Vice President

Jingjing Wang

Senior Associate

Yvonne Koh, Ph.D.

Associate

Susan Molineaux, Ph.D.

Scientific Advisor

Jaume Pons, Ph.D.

Scientific Advisor

Doug Treco, Ph.D.

Scientific Advisor

Hong I. Wan, Ph.D.

Scientific Advisor

Samira Kaissi

Entrepreneur in residence.

THE LATEST DEVELOPMENTS


LIGHTSTONE NEWS



Portfolio News Events

--------------------------------------------------------------------------------

202220212020More

10.11.22
Nimbus Therapeutics Announces Research Collaboration and License Agreement with
Lilly for Small Molecule Activators of AMPK



10.03.22
Cala Health’s real-world study validates its wearable’s long-term efficacy



09.14.22
ClavystBio launches to translate life sciences breakthroughs into health impact



09.06.22
Earlens Shares FDA Historical Ruling on OTC Hearing Aids



08.12.22
Vigil Neuroscience Announces $75 Million Private Placement Financing



08.10.22
Gemini Therapeutics and Disc Medicine Announce Merger Agreement



08.09.22
Merck is back in Alzheimer’s saddle with $1B+ Cerevance pact, years after
dropping the BACE



07.28.22
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class
Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for
Patients with Advanced Solid Tumors



07.28.22
Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne
Bruhn, Ph.D.



06.13.22
ProVerum: First Enrolment in the ProVIDE Clinical Study for BPH Treatment



06.13.22
NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic
Vertebrogenic Low Back Pain



06.10.22
Cala Health Tackles Hand Tremors With Bioelectronic Treatment



06.07.22
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia



06.05.22
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and
Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic
Malignancies



05.23.22
SK Biopharmaceuticals partners with Cala to fuel innovation in neurology



05.23.22
Gene Therapy Lowers Toxic RNA Due to C9ORF72 Mutations in ALS



05.19.22
Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND)
Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist
Antibody Conjugate for Patients with Advanced Solid Tumors



05.16.22
Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell
Therapies For Treating Solid Tumors



05.06.22
New device aims to provide better sound than hearing aids



04.27.22
Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer



04.20.22
Vigil Neuroscience Expands Leadership Team and Board of Directors



04.13.22
Raleigh medical device company Contego Medical raises more than $15M



04.05.22
Catamaran Bio Appoints Frank Lee as Chair of Its Board of Directors



04.05.22
Willow Innovations, Inc. Launches “Register for More” Campaign; Enlists Comedian
and New Mom Iliza Shlesinger to Create its First TV Ad



04.04.22
New Research Presented at AAN Demonstrates Burden Associated with Essential
Tremor and the Unmet Patient Need



03.29.22
Willow® Expands Product Suite and Unveils Willow Go™, Its Fully In-Bra Wearable
Breast Pump for Only $329



03.28.22
Cala Health announces new chief commercial, financial officers amid leadership
expansion



03.14.22
Shoulder Innovations Announces FDA Clearance of New InSet™ Stemless Humeral
Implant



03.14.22
Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the
University of Minnesota and Secures an Exclusive Patent License to Next
Generation Manufacturing Technologies



03.01.22
Cala Health Is Building Momentum By Expanding Affordable Access for Patients
with Essential Tremor



02.28.22
Catamaran Bio Announces Appointment of Michael DeRidder, PhD, as Senior Vice
President, Corporate Strategy and New Product Planning



02.08.22
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851



02.07.22
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of
Directors



01.12.22
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial
With CYT-0851



01.11.22
ProVerum Raises €30M in Series A Funding Led by Gilde Healthcare & Lightstone
Ventures



01.11.22
The Top 25 Women Leaders in Medical Devices of 2022



01.07.22
Vigil Neuroscience Announces Pricing of Initial Public Offering



01.06.22
Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor
Program and Provides Additional Business Updates



01.03.22
Relievant Medsystems’ Intracept receives new CPT codes to aid reimbursement
efforts



12.16.21
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to
Board of Directors



12.15.21
Earlens Wins “Best CEO” Award



12.13.21
Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf
CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers



11.16.21
Cala Health Raises $77M to Expand Patient Access and Fuel Continued Innovation



11.15.21
Alchemab Therapeutics Appoints Young T. Kwon, PhD as Chief Financial and
Operating Officer



11.04.21
Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data
Presentation at ASH 2021



10.19.21
Willow® Introduces the Perfect Pumping Bra to Give Moms Ultimate Support When
Pumping with Willow



09.20.21
Cyteir Therapeutics Selected to Join Russell 2000® Index



09.16.21
Reverse Shoulder Implant Reduces Glenoid Micro-Motion



09.14.21
Lightstone Ventures Raises $375 Million Fund



09.14.21
Lightstone Ventures unveils $375M third fund, this time expanding its wishlist
in blossoming CNS field



09.14.21
After 3 big exits, Lightstone snags largest fund yet with $375M geared toward
next biotechs, medtechs



09.14.21
Lightstone Ventures Raises $375 Million Fund



09.14.21
Cala Health wearables shown to decrease tremor movement



09.14.21
Lightstone Ventures’ raises $375M for its largest fund yet



09.10.21
New device for hearing loss acts like a contact lens for the ear



09.07.21
Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief
Financial Officer



08.31.21
Shoulder Innovations Relocates Corporate Headquarters



08.30.21
Gemini Therapeutics Announces Presentation of Previously Released Data from Its
Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit



08.26.21
Willow Pump CEO Laura Chambers Wants to Bring Dignity Back to Breastfeeding



08.18.21
Vigil Neuroscience Completes $90 million Series B Financing to Advance a
Pipeline of Microglia-targeted Medicines to Treat Rare and Common
Neurodegenerative Diseases



08.18.21
Vigil raises $90M in neuroscience ‘renaissance.’ Is an IPO around the corner?



08.02.21
Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President,
Technical Operations and Manufacturing



08.02.21
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel
Samuraciclib Combination to Treat HR+ Breast Cancer



07.21.21
Going for the Liquid Gold: Willow Sends Breast Pumps to Olympic Athletes



07.20.21
The 18 most innovative medical devices of 2021



07.14.21
Earlens wins “Best Leadership Team” and “Best CEOs for Diversity” awards



07.13.21
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline
Including Multiple Clinical Programs



07.06.21
Locanabio Expands Leadership Team with Appointment of Chief Scientific Officer
and Chief Medical Officer



06.24.21
Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR‑NK Cell
Manufacturing Technologies



06.24.21
52 Women-Led Startups Driving The Future Of HealthTech And FemTech



06.22.21
Alchemab’s new well-connected CEO will lead biotech on journey to address
hard-to-treat diseases



06.18.21
Med-Tech Innovation News spoke to Renee Ryan, CEO of Cala Health, about its work
tackling chronic diseases.



06.17.21
Cala Health and University of California, San Francisco Announce Partnership to
Develop Next-Generation, Smart Neuromodulation Therapies



06.17.21
Cyteir Therapeutics Announces Pricing of Initial Public Offering



06.15.21
Cyteir Therapeutics Aims For $126 Million IPO



06.14.21
The Top 25 Women Leaders in Consumer HealthTech of 2021



06.10.21
Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee
Ryan, CEO of Cala Health



06.07.21
Cala Health Announces Expansion of Executive Team with Steve Higa and Greg
Schulte



06.05.21
Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of
CYT-0851



06.03.21
Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for
Treatment of Uterine Fibroids with the Sonata System



06.02.21
Willow® Launches New Sizing Inserts To Reach More Moms



06.01.21
New Guidance from the American College of Obstetricians and Gynecologists for
Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation
as a Uterus-Preserving Treatment Option



05.28.21
Oncology biotech Cyteir Therapeutics files for a $100 million IPO



05.20.21
Cala Health Reports New Data Presented at ISPOR, Highlighting Essential Tremor
(ET)-Related Comorbidities and Economic Burden



05.20.21
Patients With Essential Tremor Experience High Economic Burden



05.13.21
Study demonstrates significant listening advantages with Earlens hearing
technology



05.13.21
A non-opioid pain startup believes it can top the bupivacaine market — and it’s
thinking in terms of weeks, not days



05.12.21
The Ultimate List of Private Medtech Companies to Watch (Updated)



05.11.21
Catamaran Bio’s Scientific Founder Leads Pivotal Advancements in Non-viral
Engineering of CAR-NK Cells Using Novel Transposon Technology



05.10.21
Relievant Medsystems Names Tyler Binney President and CEO



05.10.21
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of
ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of
Patients with Advanced Head and Neck Squamous Cell Carcinoma



05.10.21
Shoulder Innovations Announces Exclusive License Agreement for Genesis Software
Innovations PreView Shoulder™ Software



05.05.21
AstraZeneca taps antibody-mining startup Alchemab to dig into prostate cancer



05.05.21
Locanabio Announces Upcoming Preclinical Data Presentations at American Society
of Gene and Cell Therapy Annual Meeting



05.03.21
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of
Board of Directors



04.26.21
Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer



04.22.21
Breast pump innovator Willow gets additional $26.8 million in funding



04.16.21
Contego Medical Receives CE Mark Approval for Next Generation Carotid Stent



04.15.21
Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer



04.15.21
New Data Demonstrate How Cala Trio™ Enables a More Frequent Assessment of Hand
Tremor Compared with In-Person Assessments in Patients with Essential Tremor and
Supports Feasibility of Telemedicine Approaches for Essential Tremor Management



04.15.21
Gynesonics Announces Publication of SAGE Global Registry Preliminary Results:
Real-World Usage Corroborates the Safety and Applicability of Sonata
Transcervical Fibroid Ablation



04.15.21
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for
identifying disease-modifying antibody therapeutics



04.12.21
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer



04.10.21
Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody
Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American
Association for Cancer Research (AACR)



04.08.21
Gynesonics Announces Publication of Clinical Study Analysis Demonstrating
Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic
Uterine Fibroids



03.18.21
Gynesonics Appoints Susan Stimson to Its Board of Directors



03.13.21
7 Companies Developing Bioelectronic Devices



03.09.21
Gynesonics Announces Centers for Medicare and Medicaid Services Final Rule
Approves Ambulatory Surgery Centers as a Site of Service for Transcervical
Uterine Fibroid Ablation with Device Intensive Designation



03.05.21
Targeted Lung Denervation Found Effective, Safe Over 3 Years of Follow-up



03.04.21
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of
Cancer Immunotherapeutics



02.11.21
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance
Clinical Trials of Lead RAD51 Program



02.10.21
Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry
Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic
Variants



02.09.21
Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer



02.08.21
Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused
on Age-Related Macular Degeneration



02.04.21
Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief
Executive Officer



02.03.21
Willow Gears Up for Massive Growth In 2021 with Three Strategic Hires



02.02.21
SetPoint Medical enrols first patient in study of bioelectronic platform



02.01.21
Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On
to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for
Progressive Vision Loss Due to Macular Atrophy



01.27.21
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal
Trial for its Novel Bioelectronic Platform



01.26.21
The Top 25 Women Leaders in Medical Devices of 2021



01.21.21
Gynesonics Announces That Detroit Medical Center Huron Valley-Sinai Hospital has
Introduced Sonata, A New Innovative, Incision-Free Treatment for Symptomatic
Uterine Fibroids



01.12.21
Runway Growth Capital Announces a Senior Secured Term Loan of $50 Million to
Gynesonics



01.07.21
Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for
the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients With
Complement Factor H (CFH) Loss of Function Gene Variants



01.04.21
Ligature Therapeutics Launches, Raises USD $6M in Seed Financing



01.04.21
EXPERIMENTAL DRUG DEVELOPMENT CENTRE LAUNCHES SPIN-OFF TO DEVELOP TARGETED
PROTEIN DEGRADERS FOR TREATING INTRACTABLE DISEASES



12.16.20
Eyeing phase 3, Atsena raises $55M financing for blindness gene therapy



12.14.20
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of
Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and
Retinal Diseases



12.09.20
ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock



12.01.20
How a Peninsula startup with a fresh $62M round wants to get cancer to pay a
toll



12.01.20
Tallac Therapeutics launches with $62M run by ALX Oncology vets, with an eye on
next-gen cancer



11.23.20
Catamaran Bio sails into the CAR-NK waters with a $42M launch round



11.23.20
Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf
CAR-NK Cell Therapies to Treat Solid Tumors



11.17.20
Willow® Partners with The Motherly Shop to Expand Its DTC Offerings



11.16.20
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition
Study



11.05.20
Medicare Proposal Could Spur Medical-Device Investment



11.02.20
Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to
Support Clinical Development of Arginase Inhibitor, CB-280



11.02.20
Shoulder Innovations Announces Equity Financing of $21.6M



10.29.20
Relievant Medsystems Announces $70M Financing to Accelerate U.S.
Commercialization of Intracept Procedure



10.22.20
Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy
to Treat Action Tremors in Parkinson’s Disease Read more:
http://www.digitaljournal.com/pr/4850531#ixzz6bdadGbzb



10.15.20
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating
Publicly Listed Precision Medicine Company Focused on Age-Related Macular
Degeneration



10.15.20
Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip



10.15.20
Lilly Announces Agreement to Acquire Disarm Therapeutics



10.14.20
Nimbus Therapeutics Announces $60 Million Private Financing From New Investors
to Advance Expanded Pipeline



09.22.20
Willow, the startup making the wearable breast pump, raises $55 million



09.14.20
Cala Health’s wrist-worn stimulator improves tremor control in real-world study



07.22.20
The Galien Foundation Introduces 2020 Prix Galien USA Nominees in “Best
Biotechnology Product,” “Best Pharmaceutical Agent,” and “Best Medical
Technology” Categories



07.21.20
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300
Million



07.21.20
Gilead adds to string of cancer drug deals with Tizona stake



07.17.20
Immuno-oncology biotech ALX Oncology prices upsized IPO at $19, above the range



07.13.20
Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for
the Treatment of Cystic Fibrosis



07.10.20
Breast pump startup Willow’s new CEO, Laura Chambers, on innovation for women
and mothers



07.07.20
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality
Program in Cancer and Expands Senior Leadership Team



06.25.20
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers



06.22.20
Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust
Inhibition of Tumor Growth In Vivo



06.16.20
How Airbnb exec Laura Chambers landed her first CEO job at femtech startup
Willow just as the pandemic hit



06.15.20
Contego Medical Announces the Start of Enrollment in the PERFORMANCE II Carotid
Stenting Clinical Trial



06.12.20
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General
Counsel



06.08.20
Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across
Oncology, Immunology and Metabolism



06.08.20
Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial
Device



06.08.20
Nimbus CEO Keiper: ‘We’re not just a one-hit wonder’



05.19.20
An ER doctor who’s a new mother shares what it’s like to pump milk at work while
risking exposure to coronavirus



05.18.20
Willow® Partners with Aeroflow Breastpumps to Offer Its Life-Changing Wearable
Breast Pump Through Insurance



05.15.20
Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1
Inhibitor With Robust In Vivo Activity



05.07.20
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer



04.28.20
Gemini Therapeutics Appoints David Lubner as Independent Director



04.14.20
Gates, GV chip into $45M round for CNS biotech Cerevance



04.06.20
Second Genome signs Gilead deal in IBD, biomarkers worth up to $1.5B-plus



04.01.20
Locana Expands Leadership Team with Appointment of Micah Mackison, as Chief
Business Officer



03.18.20
Earlens Wins Gold 2020 Edison Award for its Revolutionary Earlens® Contact
Hearing Solution



02.26.20
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research
Collaboration to Explore New Targets for Age-related Macular Degeneration



02.18.20
After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer
hopeful



02.14.20
Cala Health aims to restore functionality to essential tremor patients with
wearables



02.12.20
ALX Oncology Announces Closing of $105 Million Series C Financing



02.04.20
Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone



01.24.20
THIS WEARABLE CAN STIMULATE NERVES TO EFFECTIVELY CANCEL OUT HAND-TREMORS… AND
IT’S A WATCH TOO.



01.13.20
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief
Financial Officer



01.13.20
Earlens inks new partnership with Verily



01.10.20
Willow’s hidden breast pump changed my life at CES



01.10.20
Willow is about to launch its smartest breast pump yet—and it promises more milk
+ comfort



01.09.20
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential
Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™



01.09.20
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry
Age-related Macular Degeneration



01.05.20
Willow’s Newest Pump Promises To Be Quiet & Efficient — First Look



12.18.19
Takeda and Cerevance Team Up to Take on GI Diseases



12.17.19
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to
President of the Company’s Tyk2 Subsidiary



12.16.19
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected
Patient Population



12.10.19
Locana Expands Leadership Team with Appointment of former Casebia CEO, James
Burns, Ph.D., as Chief Executive Officer



11.18.19
MedTech Strategist Innovation Summit San Francisco 2019



11.05.19
Mom Breast Pumps While Running the New York City Marathon: ‘Anything Is
Possible’



10.22.19
Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1
Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo



10.15.19
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing
and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor



10.08.19
12 VCs who matter in biotech, but you hardly ever read about



10.03.19
Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial
of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma



09.30.19
Catabasis Pharmaceuticals Announces The Phase 3 PolarisDMD Trial Of
Edasalonexent In Duchenne Muscular Dystrophy Has Exceeded Target Enrollment



09.13.19
Gemini Therapeutics Announces Leadership Appointment



09.04.19
Cala Health Names Veteran Leader Renee Ryan as Chief Executive Officer



07.31.19
Professor Dario Campana wins prestigious Gabbay Award



06.28.19
Carrick Therapeutics Announces Plan to Establish US Operations and Appointment
of Tim Pearson as CEO



06.21.19
Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA



06.12.19
MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for
Muscular Dystrophy



06.01.19
ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial
Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors



05.21.19
Cala Health raises $50M ahead of commercial launch of its bioelectric
stimulation device



04.30.19
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s
Disease Drug CVN424



04.09.19
MedTech Strategist Innovation Summit Dublin 2019



04.08.19
Tackling the Burden and Shame of Hearing Loss



03.31.19
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is
Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors



03.18.19
Alcon Acquires PowerVision for $285 Million



03.18.19
Alcon Announces Acquisition of PowerVision, Inc.



03.05.19
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as
VP of Neuroscience



02.28.19
Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global
Movement to Raise Awareness for Rare Diseases



02.21.19
Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for
the Treatment of Cystic Fibrosis



02.11.19
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking
Treatment of COPD



01.07.19
Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and
Natural History Study of Subjects with Dry AMD and High-Risk Genotypes



01.06.19
Willow unveils a new version of its smart breast pump



01.03.19
AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop
First-in-Class Immunotherapy for Cancer Targeting CD39



11.27.18
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of
Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy



11.07.18
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination
Cohorts for the Treatment of Patients with Advanced Solid Tumors



11.03.18
Disarm Therapeutics Presents New Data Validating Role of SARM1 in Axonal
Degeneration



10.11.18
Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and
Appoints George Golumbeski as Chairman



09.25.18
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of
Parkinson’s Disease



09.25.18
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For
Edasalonexent In Duchenne Muscular Dystrophy



07.20.18
Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.



06.04.18
Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical
Trial in Patients with Advanced Solid Tumors and Lymphoma



05.14.18
MediSix Therapeutics Launches with USD$20M Series A Financing



03.14.18
Stanford/NVCA Venture Capital Symposium



03.08.18
Bound for the clinic with a new approach to synthetic lethality, Cyteir bags
$29M



03.08.18
Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases



01.30.18
FIRE1 raises $50M to develop remote heart monitoring device



12.07.17
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin
Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)



11.16.17
Willow Named TIME Magazine 2017 Best Inventions



11.15.17
12 VCs who matter in biotech, but you never read about



11.14.17
EndoGastric® Solutions Announces Further Expansion of Medicare Reimbursement for
Transoral Incisionless Fundoplication (TIF®) 2.0 Procedure



11.10.17
Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical
Trial in Patients with Advanced Solid Tumors and Lymphoma



10.17.17
Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision
med to AMD



10.05.17
Arming Bodies with CRISPR to Fight Huntington’s Disease and ALS



10.04.17
Catabasis Pharmaceuticals Reports Positive Results From Open-Label Extension Of
Phase 2 MoveDMD® Trial Evaluating Edasalonexent In Duchenne Muscular Dystrophy
And Plans To Initiate Phase 3 Clinical Trial In First Half 2018



10.03.17
Celgene pens pact to join Bristol-Myers, Pfizer in R&D race



09.27.17
One Tech Company’s Revolutionary Idea: Design For Mothers First



09.20.17
Lightstone Ventures Closes New Life Sciences Fund at $250 Million



09.11.17
MediSix Therapeutics Signs Exclusive Licensing Agreement with the National
University of Singapore



07.29.17
Biotech sector poised to deliver more health and wealth



06.05.17
Claret Medical Receives FDA Clearance to Market Sentinel Cerebral Protection
System in the U.S.



04.21.17
Gilead says first data on Nimbus NASH candidate are positive



04.10.17
Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for
the Treatment of Advanced Solid Tumors and Lymphoma



04.05.17
Nimbus in full-on drug development partnership with Charles River



03.16.17
Moximed Closes Oversubscribed $50MM Financing Round



03.16.17
Moximed closes $50m Series C



03.14.17
Comparison of Real-world Bandwidth in Hearing Aids vs Earlens Light-driven
Hearing Aid System



02.27.17
FDA Advisory Committee Strongly Supports Granting De Novo Application For The
First Cerebral Protection System For Transcatheter Aortic Valve Replacement
(TAVR)



01.23.17
PowerVision – FierceMedicalDevices’ 2016 Fierce 15



01.09.17
Foundry SING1 Launches, Targets Asian Clinical Needs



01.05.17
The Willow could be the iPhone of breast pumps



01.05.17
Willow’s smart breast pumps slide into moms’ bras



01.04.17
Willow breast pump is the hands-free wearable that mothers really need



12.22.16
Is Med Tech Venture Investment Waning?



12.20.16
Finishing Strong in 2016: NVCA Policy Victories in the Last Few Weeks



12.02.16
Takeda and Lightstone join forces to fund and launch neuroscience upstart



11.17.16
Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for
RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria



11.01.16
Results from U.S. Pivotal IDE Trial Show That Sentinel Cerebral Protection
System Protects Patients During Transcatheter Aortic Valve Replacement



11.01.16
Nimbus Therapeutics Announces $200 Million Milestone Payment from Gilead
Sciences for Allosteric ACC Inhibitor Program in Non-alcoholic Steatohepatitis
(NASH)



11.01.16
Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into
PhII NASH trial



10.26.16
Ra Pharmaceuticals Announces Pricing of Initial Public Offering



10.19.16
SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease



10.18.16
Durable Treatment Of GERD With TIF 2.0: A Surgical Products Q&A



10.11.16
Second Genome Partners with King’s College London to Evaluate the Influence of
the Microbiome in Landmark EAT Study



10.11.16
Relievant Medsystems raises $36m



10.04.16
New Startup Carrick Therapeutics Launches With $95 Million and Taps Former
AstraZeneca PLC-Eli Lilly Exec as CEO



10.03.16
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue



09.26.16
EndoGastric Solutions Announces Publication of Long-Term Data Demonstrating TIF®
2.0 Procedure Offers Durable Treatment of Chronic GERD



09.20.16
CLARET MEDICAL SUBMITS MARKETING APPLICATION TO FDA FOR US CLEARANCE OF FIRST
CEREBRAL PROTECTION SYSTEM FOR TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)



09.14.16
CLARET MEDICAL ANNOUNCES SENTINEL PIVOTAL IDE TRIAL TO BE FEATURED IN
LATE-BREAKING TRIAL SESSION AT TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT)
CONFERENCE



09.07.16
Lightstone Ventures Adds Susan Molineaux as Scientific Advisor



09.06.16
Earlens Selects iBASEt to Support 3D Printing of Revolutionary Hearing Aid



09.06.16
Monsanto Collaborates with Second Genome to use Microbiome Technology Platform
to Accelerate Protein Discovery



09.05.16
Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in
Obstructive Lung Disease at ERS



08.29.16
Endovascular Filter Device Helps Prevent Periprocedural Stroke



08.24.16
Device treats severe heartburn at the source



08.24.16
Second Genome’s new CEO looks to neighboring Genentech as a model for pioneering
a new field



08.03.16
First COPD Patient Treated in Holaira’s Sham Controlled Trial of Targeted Lung
Denervation



07.25.16
BioCentury Emerging Company Profile of Alexo Therapeutics



07.25.16
Calithera Biosciences Announces FDA Acceptance of Investigational New Drug
Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune
Metabolic Checkpoint



07.21.16
Relievant Medsystems wins FDA clearance for Intracept ablation device for low
back pain



07.08.16
Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress
on Neuromuscular Diseases



07.05.16
EndoGastric Solutions touts U.S. reimbursement win



07.04.16
Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly
Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production



06.16.16
Earlens raises $51M to launch laser-based hearing aid after FDA nod



05.18.16
Barry Cheskin, CEO, president and co-founder of PowerVision, provides details on
his company’s new partnership with Alcon.



05.12.16
FDA Clears Next-Generation Version of EndoGastric Solutions’ EsophyX® Device



05.09.16
Moximed’s AtlasTM Knee System Improves Pain Scores and Returns Function to
Pre-Arthroplasty Patients with Medial Knee Osteoarthritis



04.22.16
Exits and IPOs the best medicine for Ireland’s medtech hub (video)



04.21.16
Novartis’ Alcon Partners With Eye Device Startup PowerVision



04.20.16
Pfizer, Roche Embrace The Microbiome, Leading $43M Bet On Second Genome



04.12.16
FIRE1 Closes Series B Financing, Announces New CEO



04.12.16
Medtronic backs stealthy Foundry startup as it nabs $7.5M for novel remote
patient monitoring



04.12.16
MINNEAPOLIS: Venture firm Lightstone taps med exec as partner



03.23.16
GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott
Schorer as President & Chief Executive Officer



03.09.16
Tizona signals full court press against regulatory T cells with $43M series B



03.08.16
With $70M in VC cash, Tizona takes a fresh approach to immuno-oncology



03.08.16
TIZONA THERAPEUTICS, INC., COMPLETES $43 MILLION SERIES B FINANCING



03.02.16
Lightstone Ventures Names Stacy Enxing Seng as Venture Partner



02.18.16
Crossing paths LINKING INFLAMMATION AND OXIDATION IN ALS



02.18.16
New life sciences fund gets $71m boost



02.18.16
Experienced med tech investor Lightstone Ventures closes $50M Singapore fund



02.16.16
Stealth Stanford spinout Cala Health raises $18M for wearable device that treats
hand and wrist tremors



02.09.16
Unraveling the Mysterious Function of the Microbiome



01.19.16
EarLens hearing aid uses laser light to transmit sound



12.15.15
Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist



12.14.15
CE Mark in hand, Moximed hatches U.S. approval strategy for knee stabilization
implant



12.10.15
ACCOMMODATIVE IOL PROVIDES GOOD VISUAL ACUITY



12.10.15
Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH
Annual Meeting



12.01.15
EndoGastric Solutions gets $50M for “natural orifice” device to treat GERD



11.18.15
Moximed Announces CE Mark and First Commercial Use of AtlasTM Knee System



10.26.15
Promise of new non-addictive painkillers to address opiate crisis highlighted in
panel



10.20.15
Nimbus Therapeutics Announces Global License Agreement with Genentech



10.15.15
EndoGastric Solutions Announces New Sham-Controlled European Study Demonstrates
Transoral Incisionless Fundoplication (TIF) Procedure as Effective Alternative
for Daily PPI Treatment



10.15.15
Five Prime, Bristol Shake Hands Again in New $350M Cancer Pact



10.15.15
Claret Medical Release: New Study Shows Definitive Neurocognitive Benefit For
Patients Protected By Sentinel Cerebral Protection System During Transcatheter
Aortic Valve Replacement (TAVR)



10.14.15
FierceMedicalDevices’ 2015 Fierce 15



09.29.15
FDA Permits Marketing Of New Laser-Based Hearing Aid With Potential For Broad
Sound Amplification



09.09.15
EndoGastric Solutions Announces AMA Assignment of CPT Code and Short Form
Descriptor



08.31.15
Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.



08.31.15
Bristol-Myers forges $1.25B deal to beef up fibrosis pipeline in Promedior
buyout



08.25.15
Medtronic to buy Twelve for $408M+, joining Abbott and Edwards on the
transcatheter mitral valve bandwagon



08.06.15
Lightstone’s Lettmann Finding Opportunities in Ireland



07.23.15
Ra Pharmaceuticals Announces $58.5M Series B Financing



07.22.15
Gynesonics gets $43M to back pivotal trial of uterine fibroid ablation device



06.25.15
Catabasis Pharmaceuticals Announces Pricing Of Initial Public Offering



06.19.15
Medicine’s next frontier: The microbiome (Second Genome featured)



05.07.15
Moximed Closes $33MM Financing Round



04.17.15
EndoGastric skips toward positive study review for GERD device



03.18.15
Evotec pairs up with Second Genome to gut out some R&D



03.18.15
Pfizer joins a powerhouse syndicate backing $43M round for Nimbus



03.12.15
GERD Device Maker Uses Clinical Data to Prove Its Point



03.01.15
A Fluid-Based Accommodating IOL



01.28.15
Flex Pharma Announces Pricing Of Initial Public Offering



01.22.15
GERD transoral surgical startup releases sham-controlled data as it awaits
reimbursement code



01.21.15
EndoGastric Solutions Announces Publication of Landmark Data in Gastroenterology
Demonstrating Superiority of Transoral Incisionless Fundoplication For Treatment
of Troublesome Regurgitation



01.12.15
Second Genome Advances Lead Microbiome Drug Development Program in Phase I
Clinical Trial as a Treatment for Inflammatory Bowel Disease



01.07.15
What’s Lurking In Your Microbiome? Possibly, A Cure For Disease



10.07.14
Holaira Announces First Patient Treatment in Randomized Study of Targeted Lung
Denervation for COPD



08.04.14
Addressing the challenges in medical innovation: VCJ



06.24.14
Human microbiome: Boon or boondoggle for drugmakers?



06.11.14
LSV Appoints Two New Venture Partners



06.11.14
NVCA Members Testify at Congressional Hearing on Incentives to Advance Medical
Research and Development



05.21.14
New €125m fund to boost innovative firms



05.16.14
Acceleron was named ‘Exit of the Year’ and Acceleron’s John Knopf was named
‘Entrepreneur of the Year – Healthcare.’ at 2014 NEVY Awards



05.02.14
Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal



05.01.14
EndoGastric Solutions Names Industry Veteran Skip Baldino CEO



05.01.14
VC Lightstone lands $172M fund with an eye on biotech startups



05.01.14
Susan Molineaux – FierceBiotech’s 2011 Women in Biotech



04.22.14
Gynesonics Names Christopher M. Owens President, Chief Executive Officer



04.03.14
Plymouth-based Holaira raises $42 million



03.27.14
The Top Life Sciences Investors Of 2014



03.26.14
‘We Need More Women In Venture Capital’ Say Female Midas Listers



03.25.14
Is Calithera the next biotech IPO hopeful?



03.24.14
Acceleron, Celgene and Collaborators Announce Two Publications in Nature
Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in
Beta-thalassemia and Myelodysplastic Syndromes



03.17.14
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to
Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways



01.09.14
Covidien, NEA and Lightstone are backing a stealthy Irish med tech startup




MENLO PARK

LSV Capital Management, LLC.
2884 Sand Hill Road, Suite 121
Menlo Park, CA 94025

T: 650.388.3676
F: 650.388.3675

View Map


BOSTON

LSV Capital Management, LLC.
500 Boylston St. Suite 1380
Boston, MA 02116

T: 617.933.3770
F: 617.933.3769

View Map


IRELAND

Lightstone Capital Management Ireland, Ltd.
9 Pembroke Street
Dublin 2

View Map


SINGAPORE

Lightstone Singapore Pte, Ltd.
OCBC Centre #27-07, 65 Chulia St
Singapore 049513

View Map

Lightstone Ventures is committed to advancing a more diverse, equitable &
inclusive venture capital ecosystem. As part of this commitment, we have signed
the #VCHumanCapital Pledge to submit our firm’s demographic and talent
management details to support the industry’s data collection and tracking
efforts. As an industry, we can only improve what we measure, and the 2020 VC
Human Capital Survey—powered by NVCA, Venture Forward, and Deloitte—is a
critical component to tracking and measuring our progress.

Learn more about the survey and see the full list of VC firms who have pledged
their participation here:
https://nvca.org/nvca-and-venture-forward-vchumancapital-pledge

© 2022 Lightstone Ventures      Terms       Login
Scroll to top